Swedish Orphan Biovitrum AB
SOBI.STDrugs in Pipeline
20
Phase 3 Programs
14
Upcoming Catalysts
3
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
SEL-212 high-dose
Chronic Gout
SEL-212 low-dose
Chronic Gout
Nitisinone
Hereditary Tyrosinemia, Type I
palifermin
Mucositis
cisplatin chemotherapy
Mucositis
Pegcetacoplan
Transplant-Associated Thrombotic Microangiopathy
Palifermin before only
Multiple Myeloma
Emapalumab
Macrophage Activation Syndrome
Cyclophosphamide
Cancer
NI-0501
Primary Haemophagocytic Lymphohistiocytosis
Efanesoctocog alfa
Hemophilia A, Severe
Anakinra
Still's Disease, Juvenile Onset
Physician's Choice medications
Primary Myelofibrosis
Pacritinib
VEXAS
SOBI003
Sanfilippo Syndrome Type A (MPS IIIA)
rhBSSL
Replacement Therapy in Preterm Infants
BVT.115959
Diabetic Neuropathic Pain
Paclitaxel
Dysphagia
Anakinra 100 mg
Acute Gouty Arthritis
Methotrexate
Graft Versus Host Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SEL-212 high-dose | Phase 3 | Chronic Gout | - | - |
SEL-212 low-dose | Phase 3 | Chronic Gout | - | - |
Nitisinone | Phase 3 | Hereditary Tyrosinemia, Type I | - | - |
palifermin | Phase 3 | Mucositis | - | - |
cisplatin chemotherapy | Phase 3 | Mucositis | - | - |
Pegcetacoplan | Phase 3 | Transplant-Associated Thrombotic Microangiopathy | - | - |
Palifermin before only | Phase 3 | Multiple Myeloma | - | - |
Emapalumab | Phase 3 | Macrophage Activation Syndrome | - | - |
Cyclophosphamide | Phase 3 | Cancer | - | - |
NI-0501 | Phase 3 | Primary Haemophagocytic Lymphohistiocytosis | - | - |
Efanesoctocog alfa | Phase 3 | Hemophilia A, Severe | - | - |
Anakinra | Phase 3 | Still's Disease, Juvenile Onset | - | - |
Physician's Choice medications | Phase 3 | Primary Myelofibrosis | - | - |
Pacritinib | Phase 3 | VEXAS | - | - |
SOBI003 | Phase 2 | Sanfilippo Syndrome Type A (MPS IIIA) | - | - |
rhBSSL | Phase 2 | Replacement Therapy in Preterm Infants | - | - |
BVT.115959 | Phase 2 | Diabetic Neuropathic Pain | - | - |
Paclitaxel | Phase 2 | Dysphagia | - | - |
Anakinra 100 mg | Phase 2 | Acute Gouty Arthritis | - | - |
Methotrexate | Phase 2 | Graft Versus Host Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Swedish Orphan Biovitrum AB's drug pipeline?→
CatalystAlert tracks 20 drug candidates in Swedish Orphan Biovitrum AB's (SOBI.ST) pipeline across Phase 3, Phase 2. Its lead program is SEL-212 high-dose (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Swedish Orphan Biovitrum AB's next FDA catalyst?→
Swedish Orphan Biovitrum AB's (SOBI.ST) next tracked catalyst is a Phase 3 expected October 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SOBI.ST biotech catalysts?→
Add SOBI.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Swedish Orphan Biovitrum AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.